TICKERNERD
Menu
PIIIPIIIHealthcare · Medical Care Facilities

PIII Stock Forecast: P3 Health Partners, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$10
−1.35% on the day

The 2 Wall Street analysts covering P3 Health Partners, Inc. hold a median 12-month price target of $18 — +76.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$2.1B
Ticker Nerd rank
52 / 100
Median analyst target
$18
Analysts covering
2
Total return, dividends reinvested
1W
−4.5%
1M
+1.3%
YTD
+192.3%
1Y
+39.5%
From 52W high
−38.1%
From 52W low
+571.1%
$2
$16
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PIII stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores P3 Health Partners, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
52 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
96
Size
79
Issuance
67
Momentum
66
Accruals
52
Volatility
38
Revisions
36
Value
22
Quality
18

Growth (96): Sales and profits are climbing, and climbing faster than before.

Quality (18): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PIII stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PIII, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25Oct 25Jan 26Apr 26Jul 26PIIIHigh $23Median $18Low $13

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
1 Buy1 Hold0 Sell
Low $13Median $18High $23

The green dot is the last close — the median target sits +76.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 May 2026TD CowenMaintainsHold—
22 May 2026TD CowenMaintainsHold$3.00 → $14
15 May 2026Lake StreetMaintainsBuy—
15 May 2026Lake StreetMaintainsBuy$4.00 → $14
2 Apr 2026TD CowenMaintainsHold—
27 Mar 2026Lake StreetMaintainsBuy—
17 Nov 2025Lake StreetMaintainsBuy—
28 Aug 2025Lake StreetAssumesBuy$20
21 Apr 2025Lake StreetMaintainsBuy—
20 Nov 2024TD CowenMaintainsHold—
1 Apr 2024BTIGDowngradeNeutral—
14 Mar 2024Lake StreetMaintainsBuy—
1 Sept 2023BTIGInitiatesBuy—
30 June 2023TD CowenInitiatesMarket Perform—
4 Jan 2022William BlairInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PIII appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PIII analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

P3 Health Partners, Inc. (PIII) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.2×

Cheaper than 78% of US stocks

Price / sales
1.4×

Cheaper than 63% of US stocks

Price / book
−0.3×

Cheaper than 94% of US stocks

EV / EBITDA
−5.9×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
8.6%

Higher than 48% of US stocks

Earnings growth (YoY)
3.5%

Higher than 40% of US stocks

Gross margin
—
Operating margin
10.7%

Higher than 65% of US stocks

Net margin
−6.6%

Higher than 23% of US stocks

Returns & dividend
Return on equity
−192.6%

Higher than 7% of US stocks

Return on assets
−13.4%

Higher than 24% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PIII vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Care Facilities
CompanyMarket capTKN rank
PIIIP3 Health Partners, Inc.$2.1B
52
BTMDbiote Corp.$57.2M
71
PARKPark Dental Partners, Inc.$98.0M
12
JYNTThe Joint Corp. (United States)$119.1M
88
DCGODocGo, Inc.$42.5M
36
CCELCryo-Cell International, Inc.$36.8M
75
WWWW International, Inc.$157.1M
61

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own P3 Health Partners, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PIII news & analysis

P3 Health Partners Q2 Earnings Call Highlights

MarketBeat · 11 Aug 2026positive

P3 Health Partners reported second-quarter adjusted EBITDA of $54 million in its Q2 earnings call and raised its full-year 2026 outlook. The quarterly result included $45 million of favorable payer settlements and prior-year development.

Why it matters — The raised full-year 2026 outlook and the favorable payer settlements affecting quarterly results are notable for those tracking PIII's financial guidance and earnings quality.

P3 Health Partners Inc. (PIII) Q2 2026 Earnings Call Transcript

Seeking Alpha · 10 Aug 2026neutral

Seeking Alpha published the Q2 2026 earnings call transcript for P3 Health Partners Inc. (PIII). The item is a transcript of the company's quarterly earnings call and contains no additional commentary beyond its publication.

Why it matters — The transcript gives PIII watchers direct access to the company's Q2 2026 earnings discussion, including management's statements.

P3 Health Partners Announces Second Quarter 2026 Results

Business Wire · 10 Aug 2026positive

P3 Health Partners announced its financial results for the second quarter ended June 30, 2026, reporting $54 million in adjusted EBITDA. The company stated that the quarter demonstrates the business is executing according to plan, with the core business driving improved profitability quarter over quarter and reflecting structural improvements.

Why it matters — The report signals that P3's core business is generating improved quarterly profitability, which is relevant for investors tracking the company's operational execution.

FAQ

Frequently asked questions about PIII stock

What is the PIII stock price forecast for 2026-2027?

The 2 Wall Street analysts covering P3 Health Partners, Inc. have a median 12-month price target of $18, with estimates ranging from $13 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PIII stock a buy right now?

Of the 2 analysts covering P3 Health Partners, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks P3 Health Partners, Inc. 52 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PIII?

As at 22 Aug 2026, P3 Health Partners, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (96 of 100).

Will PIII stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +76.5% from the last close, and Ticker Nerd's factor model ranks P3 Health Partners, Inc. 52 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PIII stock forecast for 2030?

No analyst covering P3 Health Partners, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PIII are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $23 over the next 12 months.

How has PIII stock performed over the past year?

P3 Health Partners, Inc. returned +39.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does P3 Health Partners, Inc. do?

P3 Health Partners Inc. is a population health management company focused on delivering value-based healthcare services in the United States.

What is the latest news on PIII?

The most recent item we track (MarketBeat, 11 Aug 2026): "P3 Health Partners Q2 Earnings Call Highlights". P3 Health Partners reported second-quarter adjusted EBITDA of $54 million in its Q2 earnings call and raised its full-year 2026 outlook. The quarterly result included $45 million of favorable payer settlements and prior-year development.

Company

About P3 Health Partners, Inc.

P3 Health Partners Inc. is a population health management company focused on delivering value-based healthcare services in the United States. Headquartered in Henderson, Nevada and founded in 2020, the company works primarily with Medicare-eligible and other high-utilization patient populations. P3 Health Partners partners with primary care physicians, specialists, and other clinicians, providing them with professional support services aimed at improving care coordination and clinical outcomes. Its model integrates data and analytics, technology platforms, and physician leadership to identify patient needs, manage chronic conditions, and reduce avoidable hospitalizations. The company emphasizes a patient-centered approach, offering tools for community outreach and proactive engagement to enhance access to care. Through its capital-efficient care model, P3 Health Partners seeks to support providers in transitioning to value-based arrangements, focusing on quality of care, preventive services, and cost-effective resource utilization across its managed patient panels.

CEO Dr. Aric Coffman M.D. · 320 employees · United States · https://p3hp.org